Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients

Rachida Bouamar, Dennis Hesselink, Ron van Schaik, Willem Weimar, Ilse Heiden, JW de Fijter, DRJ Kuypers, Teun Gelder

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)

Abstract

Objective We investigated the association between genetic polymorphisms in ABCB1 and SLCO1B and mycophenolic acid (MPA) pharmacokinetics, and MPA-related diarrhea and leukopenia in 338 kidney transplant recipients. Methods A total of 338 patients participating in an international, randomized-controlled clinical trial were genotyped for ABCB1 and SLCO1B. Patients were all treated with mycophenolate mofetil and either cyclosporine or tacrolimus. MPA-area under the curve (AUCs), MPA-glucuronide AUCs and acylglucuronide-AUCs were measured on days 3 and 10, and months 1, 3, 6, and 12 after kidney transplantation. Results The risk of developing diarrhea was 1.8-fold higher in patients cotreated with tacrolimus compared with patients cotreated with cyclosporine (95% confidence interval: 1.03-3.13; P = 0.038). ABCB1 and SLCO1B SNPs were not associated with dose-adjusted exposure to MPA, MPA-glucuronide, nor acylglucuronide-MPA nor with the incidence of diarrhea or leukopenia. Conclusion Genotyping for ABCB1 or SLCO1B pretransplantation is unlikely to be of clinical value for individualization of MPA therapy. Pharmacogenetics and Genomics 22: 399-407 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Original languageUndefined/Unknown
Pages (from-to)399-407
Number of pages9
JournalPharmacogenetics Genomics
Volume22
Issue number6
DOIs
Publication statusPublished - 2012

Cite this